Zhu et al. employed transcriptomic, genetic, in situ multiplex immunohistochemistry in HCC samples from patients enrolled in the above-mentioned trials, and found a direct association of pre-existing immunity in baseline tumors, high PD-L1 mRNA levels, enriched (myeloid) inflammatory response, high CD8+/regulatory T-cell count, and high VEGFR2 expression, with atezolizumab/bevacizumab activity. The gene discussed is CD274; the disease is hepatocellular carcinoma.